AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products including a BIG Drug
While there are many advantages that we see in NATESTO over other testosterone replacement therapies, there's one key advantage that really strikes us. That is the fact that the product is the only TRT (Testosterone Replacement Therapy) currently on the market that's not only effective, but comes with no black box warnings.
The Bottom Line
The bottom line here is that AYTU has a tremendous opportunity and through this opportunity, poses a potentially incredible opportunity for investors themselves. Looking at NATESTO, it's clear that not only is this drug the safest option, it is likely to become the first option. With the sales force nearing the ability to hit the ground running and an incredible management team behind them, I believe that 2018 will be the year for AYTU; and we haven't even touched on Fiera or Mioxys yet.... those are topics for another day!